SWOG clinical trial number
CTSU/EA2201

A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

Open
Abbreviated Title
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Status Notes
May Thet Cho, MD SWOG Champion
Activated
05/13/2021

Research committees

Gastrointestinal Cancer

Treatment

Ipilimumab Nivolumab

Other Clinical Trials

S2303
SWOG Clinical Trial Number

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
CTSU/A022101
SWOG Clinical Trial Number

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)

Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
S2107
SWOG Clinical Trial Number

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
100% Accrual
Accrual
100%
Open
Phase